Northwell Health Deploys Lungpacer’s AeroPace to Accelerate Ventilator Weaning

Event summary

  • Northwell’s North Shore University Hospital (NSUH) is the first on the East Coast to use Lungpacer’s FDA-approved AeroPace device to wean patients off ventilators faster.
  • The AeroPace device reduces ventilator dependency by 43% for patients on mechanical ventilation for more than 96 hours.
  • NSUH, a Level I trauma center, treats over 90,000 patients annually and is part of Northwell Health, the largest nonprofit health system in the Northeast.
  • The device uses neurostimulation to prevent diaphragm atrophy, cutting ventilator time by an average of three days.

The big picture

Northwell Health’s adoption of Lungpacer’s AeroPace device reflects a broader trend in critical care toward technology-driven solutions for ventilator dependency. The device’s ability to reduce recovery time aligns with healthcare systems’ push to improve ICU efficiency and patient outcomes, particularly for complex cases. Northwell’s scale—28 hospitals and over 1,000 outpatient facilities—positions it as a key player in validating and scaling such innovations.

What we're watching

Adoption Pace
How quickly other hospitals adopt the AeroPace device following NSUH’s success.
Cost-Effectiveness
Whether the device’s benefits in reducing ventilator time translate into lower overall healthcare costs.
Regulatory Expansion
The pace at which Lungpacer secures additional FDA approvals for broader patient populations.

Related topics

Medical Devices